Suivi

suivi
  • 文章类型: Journal Article
    关于发达国家和发展中国家围产期心肌病(PPCM)孕产妇死亡差异的信息有限。回顾文献以定义PPCM死亡的全球患病率,并确定发达国家和发展中国家之间PPCM死亡率和危险因素的差异。对PPCM患者的英语报告死亡率数据的研究来自MEDLINE的搜索,Embase,CINAHL,Cochrane图书馆,2000年1月1日至2016年5月11日的WebofScience核心合集和Scopus。在确定的4294篇文章中,包括1.07%。主要结果是死亡;心脏移植的比率,急性心肌梗死,心力衰竭,心律失常,脑血管事件,记录栓塞和心脏骤停.研究被归类为在发达国家或发展中国家进行。来自46项研究的数据,纳入了4925名患者和13个国家。来自发达国家的22项研究(n=3417)和来自发展中国家的24项研究(n=1508);平均随访时间为2.6(范围0-8.6)年。总死亡率为9%(95%置信区间[CI]6-11%)。发展中国家的死亡率(14%,95%CI10-18%)显著高于发达国家(4%,95%CI2-7%)。危险因素(慢性高血压,非洲裔,发达国家和发展中国家之间的多重孕育和多重平等)。非洲裔女性患病率较高的研究死亡率较高(相关系数0.29,95%CI0.13-0.52)。在发展中国家,PPCM女性的死亡风险高于发达国家。非洲裔妇女的死亡风险增加。
    There is limited information about differences in maternal deaths from peripartum cardiomyopathy (PPCM) between advanced and developing countries. To review the literature to define the global prevalence of death from PPCM, and to determine the differences in PPCM mortality rates and risk factors between advanced and developing countries. Studies in the English language reporting mortality data on patients with PPCM were included from searches of MEDLINE, Embase, CINAHL, the Cochrane Library, the Web of Science Core Collection and Scopus from 01 January 2000 to 11 May 2016. Of the 4294 articles identified, 1.07% were included. The primary outcome was death; rates of heart transplant, acute myocardial infarction, heart failure, arrhythmia, cerebrovascular events, embolism and cardiac arrest were recorded. Studies were categorized as having been conducted in advanced or developing countries. Data from 46 studies, 4925 patients and 13 countries were included. There were 22 studies from advanced countries (n=3417) and 24 from developing countries (n=1508); mean follow-up was 2.6 (range 0-8.6) years. Overall mortality prevalence was 9% (95% confidence interval [CI] 6-11%). The mortality rate in developing countries (14%, 95% CI 10-18%) was significantly higher than that in advanced countries (4%, 95% CI 2-7%). There was no difference in the prevalence of risk factors (chronic hypertension, African descent, multiple gestation and multiparity) between advanced and developing countries. Studies with a higher prevalence of women of African descent had higher death rates (correlation coefficient 0.29, 95% CI 0.13-0.52). The risk of death in women with PPCM was higher in developing countries than in advanced countries. Women of African descent had an increased risk of death.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: English Abstract
    Stereotactic body radiation therapy is a modern approach for delivering ablative high doses of irradiation in small volumes. This technique is being developed for the treatment of liver tumors, such as hepatocellular carcinoma, cholangiocarcinoma, or liver metastases. It represents a real alternative to surgical resection or liver transplantation when patients are inoperable or when tumours are unresectable. It is mandatory to standardize and simplify the current methods of evaluation and monitoring in order to benefit from a better understanding of the effectiveness and of the tolerance of this new treatment modality. Several scientific societies have recently proposed recommendations for the implementation of stereotactic radiotherapy for liver tumors. We conducted a literature review to provide recommendations for follow-up after completion of a stereotactic body radiation therapy for liver tumours.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: English Abstract
    BACKGROUND: Cancer Committee of the French Association of Urology (CCAFU) conducted a literature review concerning the follow-up of urothelial carcinomas and provides recommendations for monitoring.
    METHODS: A bibliographic research in French and English using PubMed was carried out from 1990 to 2014 using the keywords \"urothelial carcinoma\", \"follow-up\", \"prognosis\", and \"recurrence\".
    RESULTS: Rhythm and tools of follow-up (cytology, endoscopy, CT-urography) for non muscle invasive bladder cancer (NMIBC) have to be adjusted to the recurrence and progression risk defined by the EORTC tables. After radical treatment of muscle invasive bladder cancer (MIBC), follow-up is based on endoscopy, cytology and CT-urography. Monitoring of the urethra must be adapted to the recurrence factors and continued for at least 5 years. The monitoring of upper tract should be continued for life. In case of conservative treatment for MIBC, early endoscopy and imaging reassessment is required. After radical treatment of upper urinary tract tumour (UTUC), cystoscopy and cytology are essential because of the frequency of bladder recurrence in the first three years. Conservative management of UTUC requires strict monitoring including flexible ureteroscopy.
    CONCLUSIONS: Oncologic follow-up of urothelial carcinomas is adapted according to tumour stage and grade, location and treatment modality thus defining the risk of recurrence over time.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号